Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    Biopharma firm UCB brings new arthritis therapy to China

    By Zhou Wenting in Shanghai | chinadaily.com.cn | Updated: 2019-12-16 16:59
    Share
    Share - WeChat

    Belgium-based global biopharmaceutical company UCB announced the commercial launch of an innovative biological therapy to treat moderate-to-severe active rheumatoid arthritis (RA) for adult patients in China, marking the expansion of company's business footprint to immune system diseases in the country.

    The injection that patients are suggested to take every two weeks is the first biological agent approved in China to be used for female RA patients both during pregnancy and lactation if clinically needed.

    Doctors said RA is an autoimmune disease that causes chronic joint inflammation and affects 5 million people in China. The number of women patients suffering from the disease is three times that of the opposite gender, and women at childbearing age usually have to face the dilemma between postponing starting a family and suspending disease treatment with traditional therapies.

    Tian Xinping, chief physician of the department of rheumatology and immunology of the Peking Union Medical College Hospital, said if the disease is not well controlled for women before and during pregnancy, it may increase the risk of adverse pregnancy outcomes, such as preterm birth, low birth weight and preeclampsia. RA also comes with high disease relapse rate after giving birth, she said.

    Taco van Tiel, vice-president and head of international markets of UCB, said the product with novel molecular structure made world debut in Switzerland 12 years ago and so far has been available in 56 countries and benefiting over 380,000 patients.

    "We're delighted to bring this novel medicine to Chinese patients living with challenging chronic inflammatory conditions. UCB has a long heritage in immunology and now China has built an active pipeline of innovative portfolios reflecting UCB's global strengths," he said.

    Wu Xin, managing director of UCB China, said about five innovative molecules, including those treating autoimmune disease and osteoporosis, are scheduled by the company to be launched in the China market over the next five years.

    "For two drugs, China is part of the global Phase III clinical trial simultaneously," he said.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    亚洲av永久无码精品漫画| 人妻丰满熟妇AV无码区乱| 国产成年无码久久久久毛片| 最近最好最新2019中文字幕免费| 色窝窝无码一区二区三区色欲| 91中文字幕在线| 国产真人无码作爱免费视频| 中文无码久久精品| 中文字幕一二三区| 久久无码精品一区二区三区| 亚洲av无码不卡| 国产成人无码区免费内射一片色欲 | 日韩高清在线中文字带字幕| 丰满熟妇人妻Av无码区| 精品欧洲av无码一区二区14| 中文字幕国产在线| 亚洲乳大丰满中文字幕| 亚洲av中文无码| 久久久久无码中| www无码乱伦| 精品久久久久久久无码| 无码国产色欲XXXXX视频| 亚洲精品无码高潮喷水在线| 直接看的成人无码视频网站| 线中文在线资源 官网| 最近中文字幕大全免费视频| av区无码字幕中文色| 欧美日韩中文字幕久久伊人| 国产乱码精品一区二区三区中文| 中文字幕一区二区人妻| 最新中文字幕av无码专区| 日韩中文字幕精品免费一区| 中文字幕一区二区人妻| 人妻少妇精品视中文字幕国语 | а中文在线天堂| 波多野结衣中文在线播放| а√天堂中文官网8| 欧美日韩不卡一区二区三区中文字| 最近2019免费中文字幕视频三| 最近中文字幕2019视频1| 无码精品国产dvd在线观看9久 |